Small Molecule Modulators Targeting CD11b/CD18 Integrin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for identifying regulators of CD11b/CD18 integrin are inefficient due to difficulties in purifying the integrin from mammalian cells and maintaining its natural conformation, and existing therapeutic approaches like antibodies and peptides face challenges in selectively modulating its activity, especially at allosteric sites like the hydrophobic SILEN pocket.
Innovation Solution
Development of specific small molecule compounds that modulate CD11b/CD18 ligand binding by targeting allosteric sites, along with a cell-adhesion-based high-throughput screening assay to rapidly identify these modulators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If purified integrin from mammalian cells is used in assays, then the assay can identify regulators of CD11b/CD18, but the integrin is difficult to purify and maintain in natural conformation
Solution Approach 1:
The patent creates a cell-based assay system that copies the natural cellular environment where integrin functions, rather than attempting to purify and maintain integrin in vitro. This approach preserves the natural conformation and function of integrin by keeping it within living cells, thereby solving the purification and conformation maintenance problems while maintaining assay reliability
2Reliability
If blocking anti-CD11b/CD18 antibodies are used, then ligand binding is inhibited, but nonselective blockade of other leukocyte functions causes severe complications
Solution Approach 1:
The patent develops small molecule compounds that selectively target specific binding sites on CD11b/CD18 integrin, providing localized and specific modulation of this particular integrin's function. This selective targeting allows inhibition of CD11b/CD18-mediated inflammatory functions without affecting other leukocyte integrins, thereby achieving therapeutic efficacy while avoiding the adverse effects of nonselective antibody blockade
3Reliability
If neutrophil inhibitory factor (NIF) is used, then excessive neutrophil activation is attenuated, but its large size and immunogenicity preclude therapeutic use
Solution Approach 1:
The patent replaces the large, complex, and immunogenic NIF protein with small molecule compounds that are chemically stable, non-immunogenic, and suitable for therapeutic administration. These small molecules achieve the same functional effect of inhibiting CD11b/CD18 activity without the drawbacks of protein-based therapies, enabling practical therapeutic use
4Reliability
If ligand-mimetic peptides or small molecules are used to block integrin binding sites, then binding inhibition is achieved, but existing peptides were not very efficacious
Solution Approach 1:
The patent optimizes the structural parameters and chemical properties of small molecule compounds to improve their binding affinity and efficacy at the CD11b/CD18 binding site. By systematically modifying molecular parameters such as size, shape, functional groups, and stereochemistry, the invention achieves significantly improved binding inhibition efficacy compared to previous peptide-based approaches
Data Source
AI summary
The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.